Oral Cavity Cancer disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: ORL007 MIFTS: 62	Oral Cavity Cancer Categories: Cancer diseases, Gastrointestinal diseases, Oral diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs Expand all tables

Sources

Aliases & Classifications for Oral Cavity Cancer

MalaCards integrated aliases for Oral Cavity Cancer:

Name: Oral Cavity Cancer ¹² ¹⁵ ¹⁷

Malignant Neoplasm of Anterior Portion of Floor of Mouth ¹²

Malignant Neoplasm of Lateral Portion of Floor of Mouth ¹²

Malignant Neoplasm of Lateral Floor of Mouth ¹²

Malignant Tumor of Anterior Floor of Mouth ¹²

Malignant Tumor of Lateral Floor of Mouth ¹²

Malignant Tumor of the Floor of the Mouth ¹²

Malignant Neoplasm of Floor of Mouth ¹²

Malignant Tumor of Floor of Mouth ⁶

Malignant Neoplasm of Mouth ⁷⁴

Oral Cavity Carcinoma ⁷⁴

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Gastrointestinal diseases Oral diseases

See all MalaCards categories (disease lists)

ICD10: ³⁴

Neoplasms

Malignant neoplasms of lip, oral cavity and pharynx

Malignant neoplasm of floor of mouth

Malignant neoplasm: Anterior floor of mouth

Malignant neoplasm: Floor of mouth, unspecified

Malignant neoplasm: Lateral floor of mouth

External Ids:

Disease Ontology ¹² DOID:8618

ICD9CM ³⁶ 144 144.0 144.1 more

NCIt ⁵¹ C9318

SNOMED-CT ⁶⁹ 93672006 93802007 93860002

ICD10 ³⁴ C04 C04.0 C04.1 more

EFO ¹⁷ EFO_0005570

UMLS ⁷⁴ C0151546 C0153368 C0153369 more

Sources

Summaries for Oral Cavity Cancer

Disease Ontology : ¹² A gastrointestinal system cancer that is located in the oral cavity.

MalaCards based summary : Oral Cavity Cancer, also known as malignant neoplasm of anterior portion of floor of mouth, is related to lip and oral cavity cancer and oral squamous cell carcinoma. An important gene associated with Oral Cavity Cancer is PIK3CA (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Racepinephrine and Epinephrine have been mentioned in the context of this disorder. Affiliated tissues include salivary gland, tongue and lymph node, and related phenotypes are Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance and Decreased viability with paclitaxel

Sources

Related Diseases for Oral Cavity Cancer

Diseases in the Oral Cavity Cancer family:

Oral Cavity Carcinoma in Situ

Diseases related to Oral Cavity Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 93)

#	Related Disease	Score	Top Affiliating Genes
1	lip and oral cavity cancer	12.5
2	oral squamous cell carcinoma	11.1
3	salivary gland carcinoma	11.1
4	breast intraductal proliferative lesion	10.6	EGFR ERBB2
5	geographic tongue	10.5	EGFR TNFRSF10B VEGFA
6	primary peritoneal carcinoma	10.5	EGFR ERBB2 VEGFA
7	breast carcinoma in situ	10.5	EGFR ERBB2 VEGFA
8	pharynx cancer	10.5	EGFR GSTM1 VEGFA
9	esophageal disease	10.5	ALDH2 EGFR ERBB2
10	oral cancer	10.5	CYP1A1 EGFR GSTM1
11	stomach disease	10.5	EGFR ERBB2 VEGFA
12	colonic disease	10.4	EDNRB EGFR VEGFA
13	progesterone-receptor negative breast cancer	10.4	EGFR ERBB2
14	breast squamous cell carcinoma	10.4	EGFR ERBB2 PIK3CA
15	nervous system cancer	10.4	EGFR PTEN VEGFA
16	sister chromatid exchange, frequency of	10.4	ALDH2 GSTM1
17	breast disease	10.4	BAX CYP1A1 ERBB2 SOD2 VEGFA
18	adenosquamous lung carcinoma	10.4	EGFR ERBB2 PIK3CA
19	breast scirrhous carcinoma	10.4	EGFR ERBB2
20	acneiform dermatitis	10.4	CYP1A1 EGFR ERBB2 PIK3CA
21	ovarian cancer 1	10.4	ERBB2 PIK3CA VEGFA
22	malignant ovarian surface epithelial-stromal neoplasm	10.4	ERBB2 PIK3CA VEGFA
23	ovary epithelial cancer	10.4	ERBB2 PIK3CA VEGFA
24	myeloma, multiple	10.4	BST2 CASP8 MCL1 VEGFA
25	serous cystadenocarcinoma	10.4	ERBB2 PIK3CA VEGFA
26	ovary adenocarcinoma	10.4	BAX ERBB2 PIK3CA
27	supratentorial cancer	10.4	EGFR PTEN SOX2 VEGFA
28	estrogen-receptor positive breast cancer	10.4	EGFR ERBB2 PIK3CA
29	cerebrum cancer	10.4	EGFR PTEN SOX2 VEGFA
30	cystadenocarcinoma	10.4	ERBB2 PIK3CA VEGFA
31	central nervous system cancer	10.4	EGFR PTEN SOX2 VEGFA
32	female reproductive system disease	10.4	EGFR ERBB2 PTEN VEGFA
33	reproductive system disease	10.4	EGFR ERBB2 PTEN VEGFA
34	endometrial adenocarcinoma	10.4	EGFR ERBB2 PTEN VEGFA
35	pancreas adenocarcinoma	10.4	EGFR ERBB2 PIK3CA VEGFA
36	mucinous stomach adenocarcinoma	10.4	PTEN VEGFA
37	adult hepatocellular carcinoma	10.4	CASP8 PIK3CA
38	grade iii astrocytoma	10.4	EGFR PTEN VEGFA
39	endocrine gland cancer	10.4	EGFR ERBB2 PTEN VEGFA
40	intestinal disease	10.3	EDNRB EGFR PIK3CA VEGFA
41	acute t cell leukemia	10.3	BAX CASP8 PTEN
42	ovarian serous cystadenocarcinoma	10.3	BAX ERBB2 PIK3CA
43	thyroid hurthle cell adenoma	10.3	PIK3CA PTEN
44	carcinosarcoma	10.3	ERBB2 PIK3CA PTEN
45	lung cancer susceptibility 3	10.3	CASP8 CYP1A1 EGFR ERBB2 PIK3CA VEGFA
46	uterine anomalies	10.3	ERBB2 PIK3CA PTEN VEGFA
47	uterine carcinosarcoma	10.2	EGFR ERBB2 PIK3CA PTEN
48	adenocarcinoma	10.2	EGFR ERBB2 PIK3CA PTEN VEGFA
49	anaplastic thyroid cancer	10.2	CASP8 PIK3CA PTEN
50	lymphoma, non-hodgkin, familial	10.2	BAX CASP8 MCL1 PIK3CA

Comorbidity relations with Oral Cavity Cancer via Phenotypic Disease Network (PDN):

Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Oral Cavity Cancer:

Sources

Symptoms & Phenotypes for Oral Cavity Cancer

GenomeRNAi Phenotypes related to Oral Cavity Cancer according to GeneCards Suite gene sharing:

²⁷

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance	GR00210-A	9.35	EGFR ERBB2 GSTM1 PTEN VEGFA
2	Decreased viability with paclitaxel	GR00179-A-1	8.92	EGFR ERBB2 FADD
3	Decreased viability with paclitaxel	GR00179-A-3	8.92	EGFR

MGI Mouse Phenotypes related to Oral Cavity Cancer:

⁴⁷ (show all 24)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	growth/size/body region	MP:0005378	10.48	ALDH2 BAX CASP8 CYP1A1 EDNRB EGFR
2	cardiovascular system	MP:0005385	10.46	ALDH2 CASP8 CYP1A1 EDNRB EGFR ERBB2
3	homeostasis/metabolism	MP:0005376	10.46	ALDH2 BAX CASP8 CYP1A1 EDNRB EGFR
4	cellular	MP:0005384	10.45	ALDH2 BAX CASP8 EDNRB EGFR ERBB2
5	endocrine/exocrine gland	MP:0005379	10.43	ALDH2 BAX CASP8 CYP1A1 EDNRB EGFR
6	mortality/aging	MP:0010768	10.42	ALDH2 BAX CASP8 CYP1A1 EDNRB EGFR
7	immune system	MP:0005387	10.39	ALDH2 BAX CASP8 CYP1A1 EDNRB EGFR
8	hematopoietic system	MP:0005397	10.38	ALDH2 BAX CASP8 CYP1A1 EDNRB EGFR
9	behavior/neurological	MP:0005386	10.36	ALDH2 BAX EDNRB ERBB2 GDF15 PIK3CA
10	embryo	MP:0005380	10.33	CASP8 EDNRB EGFR ERBB2 FADD LIN28B
11	muscle	MP:0005369	10.32	ALDH2 BAX CASP8 EDNRB EGFR ERBB2
12	integument	MP:0010771	10.31	ALDH2 CASP8 EDNRB EGFR ERBB2 MCL1
13	nervous system	MP:0003631	10.31	ALDH2 BAX CASP8 EDNRB EGFR ERBB2
14	neoplasm	MP:0002006	10.23	ALDH2 BAX CASP8 EDNRB EGFR ERBB2
15	liver/biliary system	MP:0005370	10.21	ALDH2 CASP8 CYP1A1 EGFR FADD GDF15
16	digestive/alimentary	MP:0005381	10.2	EDNRB EGFR ERBB2 FADD PTEN SOX2
17	limbs/digits/tail	MP:0005371	10.07	ALDH2 BAX EDNRB EGFR ERBB2 PTEN
18	normal	MP:0002873	10.06	CYP1A1 EGFR ERBB2 LIN28B MCL1 PTEN
19	renal/urinary system	MP:0005367	10.02	ALDH2 BAX CASP8 EDNRB EGFR GDF15
20	reproductive system	MP:0005389	9.96	ALDH2 BAX EGFR ERBB2 MCL1 PIK3CA
21	pigmentation	MP:0001186	9.85	ALDH2 EDNRB EGFR PTEN SOD2 SOX2
22	respiratory system	MP:0005388	9.81	BAX CASP8 EDNRB EGFR ERBB2 PTEN
23	skeleton	MP:0005390	9.7	ALDH2 BAX EDNRB EGFR ERBB2 FADD
24	vision/eye	MP:0005391	9.28	ALDH2 BAX EDNRB EGFR PIK3CA PTEN

Sources

Drugs & Therapeutics for Oral Cavity Cancer

Drugs for Oral Cavity Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 415)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Racepinephrine

Approved

Phase 4,Phase 2,Phase 1

329-65-7

838

Epinephrine

Approved, Vet_approved

Phase 4,Phase 2,Phase 1

51-43-4

5816

Norepinephrine

Approved

Phase 4,Not Applicable

51-41-2

439260

Dopamine

Approved

Phase 4,Phase 2

62-31-7, 51-61-6

681

Dobutamine

Approved

Phase 4,Not Applicable

34368-04-2

36811

Dopexamine

Approved, Investigational

Phase 4

86197-47-9

55483

Pentetic acid

Approved

Phase 4

67-43-6

Edetic Acid

Approved, Vet_approved

Phase 4

62-33-9, 60-00-4

6049

Bupropion

Approved

Phase 4,Phase 2

34841-39-9, 34911-55-2

444

Nicotine

Approved

Phase 4,Not Applicable

54-11-5

942 89594

Metformin

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

657-24-9

14219 4091

Calcium

Approved, Nutraceutical

Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable

7440-70-2

271

Mydriatics

Phase 4,Phase 2

Adrenergic beta-Agonists

Phase 4,Phase 2,Not Applicable

Peripheral Nervous System Agents

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

Adrenergic Agonists

Phase 4,Phase 2,Phase 3,Not Applicable

Vasoconstrictor Agents

Phase 4,Phase 2,Phase 1,Not Applicable

Anti-Asthmatic Agents

Phase 4,Phase 2

Autonomic Agents

Phase 4,Phase 3,Phase 2,Not Applicable

Neurotransmitter Agents

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1

Sympathomimetics

Phase 4,Phase 2,Not Applicable

Adrenergic alpha-Agonists

Phase 4,Phase 2,Phase 3,Not Applicable

Epinephryl borate

Phase 4,Phase 2,Phase 1

Bronchodilator Agents

Phase 4,Phase 2

Adrenergic Agents

Phase 4,Phase 2,Phase 3,Not Applicable

Respiratory System Agents

Phase 4,Phase 2,Not Applicable

Protective Agents

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1

Radiopharmaceuticals

Phase 4,Phase 1,Phase 2,Not Applicable

Anticoagulants

Phase 4,Not Applicable

Chelating Agents

Phase 4,Not Applicable,Early Phase 1

Cytochrome P-450 Enzyme Inhibitors

Phase 4,Phase 2,Phase 3

Liver Extracts

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Calcium, Dietary

Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable

HIV Protease Inhibitors

Phase 4,Phase 2,Phase 3

Hormones

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

protease inhibitors

Phase 4,Phase 2,Phase 3

Vasodilator Agents

Phase 4,Not Applicable

Dopamine Agents

Phase 4,Phase 2

Dopamine agonists

Phase 4

Cardiotonic Agents

Phase 4,Not Applicable

Blood Substitutes

Phase 4

Plasma Substitutes

Phase 4

Dextrans

Phase 4

Technetium Tc 99m Pentetate

Phase 4

Technetium Tc 99m Sulfur Colloid

Phase 4,Not Applicable

Neurotransmitter Uptake Inhibitors

Phase 4,Phase 2

Antidepressive Agents

Phase 4,Phase 3,Phase 2

Antidepressive Agents, Second-Generation

Phase 4,Phase 2

Psychotropic Drugs

Phase 4,Phase 3,Phase 2,Phase 1

Dopamine Uptake Inhibitors

Phase 4,Phase 2

Interventional clinical trials:

(show top 50) (show all 593)

#	Name	Status	NCT ID	Phase	Drugs
1	Assessment of the Effects of Pressors on Graft Blood Flow After Free Tissue Transfer Surgery	Completed	NCT01418118	Phase 4	Epinephrine;Norepinephrine;Dobutamine;Dopexamine
2	Sentinel Lymph Node Biopsy Findings in Patients With Breast Cancer	Completed	NCT02287675	Phase 4	Lymphoseek;Sulfur Colloid
3	Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking	Completed	NCT00666978	Phase 4	bupropion hydrochloride
4	Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking	Completed	NCT00365508	Phase 4	nicotine lozenge;nicotine patch
5	Stereotactic Body Radiotherapy for Head and Neck Tumors	Completed	NCT01344356	Phase 4
6	Photodynamic Therapy for Oral Leukoplakia and Erythroleukoplakia	Completed	NCT00155337	Phase 4
7	The Optimal Neck Treatments Strategy of Early Oral Cancer Based on Adverse Pathological Factor	Recruiting	NCT03017053	Phase 4
8	Cancer Chemoprevention by Metformin Hydrochloride Compared to Placebo in Oral Potentially Malignant Lesions	Recruiting	NCT03684707	Phase 4	Metformin Hcl 500Mg 24Hr Sa Tab
9	Aliskiren Study of Safety and Efficacy in Senior Hypertensives	Withdrawn	NCT01922141	Phase 4	Aliskiren;Amlodipine;Ramipril;Hydrochlorothiazide
10	Oral Cancer Screening in Mumbai, India by Primary Health Care Workers	Unknown status	NCT00655421	Phase 3
11	Oral Cancer Adjuvant Therapy (OCAT) Trial	Unknown status	NCT00193843	Phase 3
12	Efficacy of Optically-guided Surgery in the Management of Early-staged Oral Cancer - COOLS TRIAL	Unknown status	NCT01039298	Phase 3
13	Surgery and Radiation Therapy With or Without Chemotherapy in Treating Patients With Mouth Cancer	Unknown status	NCT00002747	Phase 3	cisplatin;fluorouracil
14	Surgery and Radiation Therapy With or Without Interleukin-2 in Treating Patients With Cancer of the Mouth or Oropharynx	Unknown status	NCT00002702	Phase 3
15	Effectiveness of Adjuvant Radiotherapy in Small Oropharyngeal Squamous Cell Cancer and Single Lymph Node Metastasis.	Unknown status	NCT00964977	Phase 3
16	The Feasibility of Dexmedetomidine for Awake Fiberoptic Nasal Intubation	Unknown status	NCT00815893	Phase 2, Phase 3	dexmedetomidine;Normal Saline 0.9%;propofol 1%
17	Iseganan Hydrochloride in Preventing Oral Mucositis in Patients Who Are Undergoing Radiation Therapy for Head and Neck Cancer	Unknown status	NCT00022373	Phase 3	iseganan HCl oral solution
18	PET/CT Scan-Guided Watchful Waiting or Neck Dissection of Locally Advanced Lymph Node Metastases in Treating Patients Undergoing Chemotherapy and Radiation Therapy for Primary Head And Neck Cancer	Unknown status	NCT00720070	Phase 3
19	Study of I-125 Brachytherapy Versus Intensity-modulated Radiation Therapy to Treat Inoperable Salivary Gland Cancer	Unknown status	NCT02048254	Phase 3
20	Intensity-Modulated Radiation Therapy or 3-Dimensional Conformal Radiation Therapy in Decreasing Hearing Loss in Patients Who Have Undergone Surgery for Parotid Tumors	Unknown status	NCT01216800	Phase 3
21	Erlotinib Prevention of Oral Cancer (EPOC)	Completed	NCT00402779	Phase 3	Erlotinib;Placebo
22	Workplace Tobacco Cessation And Oral Cancer Screening Study	Completed	NCT00750503	Phase 3
23	Efficacy of Zinc on Concurrent Chemo-radiotherapy Induced Taste Alterations	Completed	NCT03824925	Phase 3	Placebo oral Zinc capsule;Zinc Sulfate 220 MG
24	Post-Operative Adjuvant Concurrent Chemoradiotherapy For High Risk Oral Cavity Squamous Cell Carcinoma Patients	Completed	NCT00201383	Phase 3	cisplatin
25	Oral Mucositis in Patients Receiving Radiation Therapy for Cancer of the Mouth, Pharynx, or Larynx	Completed	NCT00004234	Phase 3
26	Phase II Trial of Allovectin-7® for Head and Neck Cancer	Completed	NCT00050388	Phase 3
27	Chemoprevention Study of Oral Cavity Squamous Cell Carcinoma	Completed	NCT00201279	Phase 3	13-cis Retino Acid
28	Neoadjuvant Erbitux Based Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer	Completed	NCT01434394	Phase 2, Phase 3	Neo-adjuvant Erbitux-based chemotherapy
29	Randomized Trial to Assess the Impact of a Screening Program on Upper Aerodigestive Tract Cancer Mortality in a High Risk Population	Completed	NCT00359645	Phase 3
30	Accelerated Radiotherapy and Concomitant Chemo-radiotherapy in HNSCC	Completed	NCT00158652	Phase 3	5FU, Paraplatin
31	Effect of Oral Vitamin C in Assessing the Severity of Oral Mucositis in Chemoradiation of Head and Neck Cancers	Completed	NCT02868151	Phase 2, Phase 3	Ascorbic Acid;Zinc acetate
32	Very Intense Radiotherapy-Chemotherapy Regimen in Advanced HNSCC	Completed	NCT00162708	Phase 2, Phase 3	CDDP, 5 Fu
33	Sargramostim in Decreasing Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer	Completed	NCT00008398	Phase 3
34	Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy	Completed	NCT01156142	Phase 3	doxepin hydrochloride
35	Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain	Completed	NCT00538850	Phase 3	Fentanyl sublingual spray;Placebo
36	Study of Nutrition Regimens in Treating Patients With Cancer of the Upper Aerodigestive Tract	Completed	NCT00765440	Phase 3
37	Acupuncture or Standard Therapy in Treating Pain and Dysfunction in Patients Who Have Undergone Neck Surgery for Head and Neck Cancer	Completed	NCT00090337	Phase 3
38	Fluconazole in Preventing Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer	Completed	NCT00002533	Phase 2, Phase 3	fluconazole
39	Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer	Completed	NCT00017511	Phase 3	cevimeline hydrochloride
40	Megestrol to Limit Weight Loss and Improve Quality of Life in Treating Patients With Head and Neck Cancer	Completed	NCT00006799	Phase 3	megestrol acetate
41	Radiation Therapy and Chemotherapy in Treating Patients With Head and Neck Cancer	Completed	NCT00002507	Phase 3	mitomycin C;porfiromycin
42	Radiation Therapy With or Without Chemotherapy in Treating Patients With Advanced Head and Neck Cancer	Completed	NCT00002476	Phase 3	fluorouracil;leucovorin calcium;methotrexate;vincristine sulfate
43	Acupuncture-Like Transcutaneous Electrical Nerve Stimulation (ALTENS) or Pilocarpine in Treating Early Dry Mouth in Patients Undergoing Radiation Therapy for Head and Neck Cancer	Completed	NCT00656513	Phase 2, Phase 3	Pilocarpine
44	Radiation Therapy and Cisplatin or Panitumumab in Treating Patients With Locally Advanced Stage III or Stage IV Head and Neck Cancer	Completed	NCT00820248	Phase 3	cisplatin
45	The Use of Human Acellular Dermal Matrix to Improve Infraauricular Depressed Deformities and Frey's Syndrome	Completed	NCT01414790	Phase 3
46	Cancer Chemoprevention by Metformin Hydrochloride in Oral Potentially Malignant Lesions	Recruiting	NCT03685409	Phase 3	Metformin Hydrochloride 500 MG;Placebo Oral Tablet
47	DOM-INNATE: Study of SGX942 for the Treatment of Oral Mucositis in Patients With Concomitant Chemoradiation Therapy for Head and Neck Cancer	Recruiting	NCT03237325	Phase 3	SGX942;Placebo
48	Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin	Recruiting	NCT03258554	Phase 2, Phase 3
49	Parenteral Nutrition for Patients Treated for Locally Advanced Inoperable Tumors of the Head and Neck	Recruiting	NCT02236936	Phase 3	Cisplatin
50	Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity	Active, not recruiting	NCT01265849	Phase 3	Cyclophosphamide;Indomethacin;Cisplatin

Search NIH Clinical Center for Oral Cavity Cancer

Sources

Genetic Tests for Oral Cavity Cancer

Sources

Anatomical Context for Oral Cavity Cancer

MalaCards organs/tissues related to Oral Cavity Cancer:

⁴²

Salivary Gland, Tongue, Lymph Node, Lung, Breast, Skin, Brain

The Foundational Model of Anatomy Ontology organs/tissues related to Oral Cavity Cancer:

²⁰

The Oral Cavity

Sources

Publications for Oral Cavity Cancer

Articles related to Oral Cavity Cancer:

(show top 50) (show all 335)

#	Title	Authors	Year
1	Oral Cavity Cancer. ( 30454788 )	Ettinger KS...Fernandes RP	2019
2	Oral cavity cancer management guidelines for low-resource regions. ( 30666743 )	Cervenka B...Moore M	2019
3	Commentary on "Number of positive lymph nodes better predicts survival for oral cavity cancer" by Hojun Lee et al. ( 30672589 )	Lydiatt WM	2019
4	Number of positive lymph nodes better predicts survival for oral cavity cancer. ( 30672597 )	Lee H...Kim SY	2019
5	Finding an oral potentially malignant disorder in screening program is related to early diagnosis of oral cavity cancer - Experience from real world evidence. ( 30732947 )	Ho PS...Yang YH	2019
6	Impact of postoperative radiation therapy for deeply invasive oral cavity cancer upstaged to stage III. ( 30773733 )	Cramer JD...Kim S	2019
7	Number of positive nodes - Current relevance in determining prognosis of oral cavity cancer after the recent AJCC staging update. ( 30846166 )	Rajappa SK...Dewan AK	2019
8	Delays in oral cavity cancer. ( 30878273 )	Gigliotti J...Makhoul N	2019
9	Factors Influencing Body Image in Post-treatment Oral Cavity Cancer Patients. ( 30889623 )	Chang YL...Chen SC	2019
10	Does Clearance of Positive Margins Improve Local Control in Oral Cavity Cancer? A Meta-analysis. ( 30912991 )	Bulbul MG...Varvares MA	2019
11	Comparison of psychosocial factors over time among HPV+ oropharyngeal cancer and tobacco-related oral cavity cancer patients. ( 30322742 )	Janz TA...Day TA	2019
12	Definitive chemoradiation for locally-advanced oral cavity cancer: A 20-year experience. ( 29706184 )	Foster C.C....Haraf D.J.	2018
13	Association of Time between Surgery and Adjuvant Therapy with Survival in Oral Cavity Cancer. ( 29313448 )	Chen M.M....Divi V.	2018
14	Detection of surgical margins in oral cavity cancer: the role of dynamic optical contrast imaging. ( 29517537 )	Pellionisz P.A....St John M.A.	2018
15	Low expression of CD40L in tumor-free lymph node of oral cavity cancer related with poor prognosis. ( 29761306 )	Rah Y.C....Ahn S.H.	2018
16	Expression profiles of selected genes in tumors and matched surgical margins in oral cavity cancer: Do we have to pay attention to the molecular analysis of the surgical margins? ( 29790687 )	Strzelczyk J.K....Owczarek A.J.	2018
17	Locoregionally advanced oral cavity cancer: A propensity-score matched analysis on overall survival with emphasis on the impact of adjuvant radiotherapy. ( 29665118 )	Shin J.Y....Diaz A.Z.	2018
18	The influence of insurance status on treatment and outcomes in oral cavity cancer: an analysis on 46,373 patients. ( 29655817 )	Shin J.Y....Diaz A.Z.	2018
19	MR lymphography for sentinel lymph node detection in patients with oral cavity cancer: Preliminary clinical study. ( 29633413 )	Bae S....Kim J.	2018
20	The influence of marital status on survival for patients aged 65 years and younger with oral cavity cancer. ( 29685504 )	Liao P.H....Lee C.C.	2018
21	The effectiveness of a saline mouth rinse regimen and education programme on radiation-induced oral mucositis and quality of life in oral cavity cancer patients: A randomised controlled trial. ( 29315944 )	Huang B.S....Chen S.C.	2018
22	Effects of a swallowing exercise education program on dysphagia-specific health-related quality of life in oral cavity cancer patients post-treatment: a randomized controlled trial. ( 29546525 )	Chen S.C....Wu S.C.	2018
23	Opioid prescribing practices in patients undergoing surgery for oral cavity cancer. ( 29756393 )	Pang J....Coffey C.S.	2018
24	Genetic analysis of surgical margins in oral cavity cancer. ( 29341160 )	Liu S.A....Lin J.C.	2018
25	Narrow Band Imaging-guided resection of oral cavity cancer decreases local recurrence and increases survival. ( 29480612 )	Farah C.S.	2018
26	Aberrant DNA methylation of the <i>p16, APC, MGMT, TIMP3</i> and <i>CDH1</i> gene promoters in tumours and the surgical margins of patients with oral cavity cancer. ( 29896273 )	Strzelczyk J.K....Owczarek A.J.	2018
27	Diagnostic Pathway of Oral Cavity Cancer in an Integrated Health Care System. ( 29616906 )	Wang K.H....Gurushanthaiah D.	2018
28	Can MR textural analysis improve the prediction of extracapsular nodal spread in patients with oral cavity cancer? ( 29872911 )	Frood R....Scarsbrook A.	2018
29	Detection of cervical lymph node metastasis from oral cavity cancer using a non-radiating, noninvasive digital infrared thermal imaging system. ( 29739969 )	Dong F....Lyu P.	2018
30	High sensitivity and negative predictive value of sentinel lymph node biopsy in a retrospective early stage oral cavity cancer cohort in the Northern Netherlands. ( 29575685 )	Boeve K....Witjes M.J.H.	2018
31	Complete atrioventricular block as an initial manifestation of recurred oral cavity cancer: a case report. ( 29986652 )	Cho JY...Park JC	2018
32	Combination of recurrent oral aphthae and dry eye syndrome may constitute an independent risk factor for oral cavity cancer in elderly women. ( 30233243 )	Qin L...Wu SY	2018
33	Swallowing ability and its impact on dysphagia-specific health-related QOL in oral cavity cancer patients post-treatment. ( 30322515 )	Chen SC...Wu SC	2018
34	Association Between Lymph Node Ratio and Recurrence and Survival Outcomes in Patients With Oral Cavity Cancer. ( 30452499 )	Ding D...Karam SD	2018
35	Clinical analysis of neck node metastasis in oral cavity cancer. ( 30637242 )	Sharma A...Paeng JY	2018
36	Author Correction: Detection of cervical lymph node metastasis from oral cavity cancer using a non-radiating, noninvasive digital infrared thermal imaging system. ( 29991743 )	Dong F...Lyu P	2018
37	Diagnostic pathway of oral cavity cancer in an integrated health care system. ( 30095106 )		2018
38	Adjuvant radiation for T1-2N1 oral cavity cancer survival outcomes and utilization treatment trends: Analysis of the SEER database. ( 30220313 )	Torrecillas V...Cannon RB	2018
39	Sentinel Lymph Node Biopsy Versus Elective Neck Dissection for Stage I to II Oral Cavity Cancer. ( 30284248 )	Cramer JD...Samant S	2018
40	Toward complete oral cavity cancer resection using a handheld diffuse reflectance spectroscopy probe. ( 30341837 )	Brouwer de Koning SG...Ruers TJM	2018
41	Trends in clinical features and survival of oral cavity cancer: fifty years of experience with 3,362 consecutive cases from a single institution. ( 30349385 )	Chen SW...Song M	2018
42	Does anatomic subsite influence oral cavity cancer mortality? A SEER database analysis. ( 30408182 )	Farhood Z...Osazuwa-Peters N	2018
43	Evaluation of early oral cavity cancer treatment quality at a single institution. ( 30408196 )	Chang S...Yaremchuk K	2018
44	Untreated oral cavity cancer: Long-term survival and factors associated with treatment refusal. ( 28865100 )	Cheraghlou S....Judson B.L.	2017
45	Metastatic Lymph Node Burden and Survival in Oral Cavity Cancer. ( 28880746 )	Ho A.S....Zumsteg Z.S.	2017
46	Recent Trends in Oral Cavity Cancer Research Support in the United States. ( 28033064 )	Fribley A.M....Kirkwood K.L.	2017
47	Comparison of facility type outcomes for oral cavity cancer: Analysis of the national cancer database. ( 28671267 )	Rubin S.J....Jalisi S.	2017
48	Differences in Survival With Surgery and Postoperative Radiotherapy Compared With Definitive Chemoradiotherapy for Oral Cavity Cancer: A National Cancer Database Analysis. ( 28426848 )	Spiotto M.T....Koshy M.	2017
49	Patterns of locoregional failure following post-operative intensity-modulated radiotherapy to oral cavity cancer: quantitative spatial and dosimetric analysis using a deformable image registration workflow. ( 28806994 )	Mohamed A.S.R....Garden A.S.	2017
50	Coinfection with Epstein-Barr Virus (EBV), Human Papilloma Virus (HPV) and Polyoma BK Virus (BKPyV) in Laryngeal, Oropharyngeal and Oral Cavity Cancer. ( 29257122 )	Drop B....Polz-Dacewicz M.	2017

Sources

Genes for Oral Cavity Cancer

Genes related to Oral Cavity Cancer (2 elite genes):

(show all 45)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	PIK3CA	Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha	Protein Coding	404.98	Pathogenic ⁶ DISEASES inferred ¹⁵
2	PTEN	Phosphatase And Tensin Homolog	Protein Coding	404.96	Pathogenic/Likely pathogenic ⁶ DISEASES inferred ¹⁵
3	EGFR	Epidermal Growth Factor Receptor	Protein Coding	23.29	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
4	VEGFA	Vascular Endothelial Growth Factor A	Protein Coding	22.6	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
5	ERBB2	Erb-B2 Receptor Tyrosine Kinase 2	Protein Coding	22.29	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
6	CASP8	Caspase 8	Protein Coding	21.8	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
7	SOX2	SRY-Box 2	Protein Coding	21.69	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
8	CYP1A1	Cytochrome P450 Family 1 Subfamily A Member 1	Protein Coding	21.56	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
9	GSTM1	Glutathione S-Transferase Mu 1	Protein Coding	21.51	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
10	MCL1	MCL1 Apoptosis Regulator, BCL2 Family Member	Protein Coding	21.13	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
11	FADD	Fas Associated Via Death Domain	Protein Coding	21.12	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
12	LIN28B	Lin-28 Homolog B	Protein Coding	20.58	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
13	GDF15	Growth Differentiation Factor 15	Protein Coding	20.52	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
14	TLR2	Toll Like Receptor 2	Protein Coding	20.26	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
15	TNFRSF10B	TNF Receptor Superfamily Member 10b	Protein Coding	20.17	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
16	ALDH2	Aldehyde Dehydrogenase 2 Family Member	Protein Coding	20.12	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
17	BAX	BCL2 Associated X, Apoptosis Regulator	Protein Coding	20.04	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
18	SOD2	Superoxide Dismutase 2	Protein Coding	19.98	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
19	EDNRB	Endothelin Receptor Type B	Protein Coding	19.91	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
20	BST2	Bone Marrow Stromal Cell Antigen 2	Protein Coding	19.89	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
21	HSP90B1	Heat Shock Protein 90 Beta Family Member 1	Protein Coding	19.73	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
22	CYP2E1	Cytochrome P450 Family 2 Subfamily E Member 1	Protein Coding	19.67	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
23	DNAJB7	DnaJ Heat Shock Protein Family (Hsp40) Member B7	Protein Coding	8.48	DISEASES inferred ¹⁵
24	TECR	Trans-2,3-Enoyl-CoA Reductase	Protein Coding	8.12	DISEASES inferred ¹⁵
25	MAML2	Mastermind Like Transcriptional Coactivator 2	Protein Coding	7.83	DISEASES inferred ¹⁵
26	MAU2	MAU2 Sister Chromatid Cohesion Factor	Protein Coding	7.76	DISEASES inferred ¹⁵
27	CRTC1	CREB Regulated Transcription Coactivator 1	Protein Coding	7.44	DISEASES inferred ¹⁵
28	TP53	Tumor Protein P53	Protein Coding	7.26	DISEASES inferred ¹⁵
29	ISL1	ISL LIM Homeobox 1	Protein Coding	6.98	DISEASES inferred ¹⁵
30	CDH1	Cadherin 1	Protein Coding	6.95	DISEASES inferred ¹⁵
31	CP	Ceruloplasmin	Protein Coding	6.7	GeneCards inferred via : Publications (show sections)
32	TNFRSF6B	TNF Receptor Superfamily Member 6b	Protein Coding	6.7	GeneCards inferred via : Publications (show sections)
33	TNFSF10	TNF Superfamily Member 10	Protein Coding	6.7	GeneCards inferred via : Publications (show sections)
34	TLR6	Toll Like Receptor 6	Protein Coding	6.7	GeneCards inferred via : Publications (show sections)
35	GSTT1	Glutathione S-Transferase Theta 1	Protein Coding	6.7	GeneCards inferred via : Publications (show sections)
36	ERCC1	ERCC Excision Repair 1, Endonuclease Non-Catalytic Subunit	Protein Coding	6.7	GeneCards inferred via : Publications (show sections)
37	IL4R	Interleukin 4 Receptor	Protein Coding	6.7	GeneCards inferred via : Publications (show sections)
38	IL18	Interleukin 18	Protein Coding	6.7	GeneCards inferred via : Publications (show sections)
39	GPX1	Glutathione Peroxidase 1	Protein Coding	6.7	GeneCards inferred via : Publications (show sections)
40	NAT2	N-Acetyltransferase 2	Protein Coding	6.7	GeneCards inferred via : Publications (show sections)
41	IL13RA1	Interleukin 13 Receptor Subunit Alpha 1	Protein Coding	6.7	GeneCards inferred via : Publications (show sections)
42	IL4	Interleukin 4	Protein Coding	6.7	GeneCards inferred via : Publications (show sections)
43	MPO	Myeloperoxidase	Protein Coding	6.7	GeneCards inferred via : Publications (show sections)
44	CAT	Catalase	Protein Coding	6.7	GeneCards inferred via : Publications (show sections)
45	HEPH	Hephaestin	Protein Coding	6.7	GeneCards inferred via : Publications (show sections)

Sources

Variations for Oral Cavity Cancer

ClinVar genetic disease variations for Oral Cavity Cancer:

⁶

#	Gene	Variation	Type	Significance	SNP ID	Assembly	Location
1	PIK3CA	NM_006218.3(PIK3CA): c.3139C> T (p.His1047Tyr)	single nucleotide variant	Pathogenic	rs121913281	GRCh37	Chromosome 3, 178952084: 178952084
2	PIK3CA	NM_006218.3(PIK3CA): c.3139C> T (p.His1047Tyr)	single nucleotide variant	Pathogenic	rs121913281	GRCh38	Chromosome 3, 179234296: 179234296
3	PTEN	NM_000314.6(PTEN): c.388C> G (p.Arg130Gly)	single nucleotide variant	Pathogenic/Likely pathogenic	rs121909224	GRCh37	Chromosome 10, 89692904: 89692904
4	PTEN	NM_000314.6(PTEN): c.388C> G (p.Arg130Gly)	single nucleotide variant	Pathogenic/Likely pathogenic	rs121909224	GRCh38	Chromosome 10, 87933147: 87933147
5	PIK3CA	NM_006218.3(PIK3CA): c.3145G> C (p.Gly1049Arg)	single nucleotide variant	Likely pathogenic	rs121913277	GRCh37	Chromosome 3, 178952090: 178952090
6	PIK3CA	NM_006218.3(PIK3CA): c.3145G> C (p.Gly1049Arg)	single nucleotide variant	Likely pathogenic	rs121913277	GRCh38	Chromosome 3, 179234302: 179234302

Sources

Expression for Oral Cavity Cancer

Search GEO for disease gene expression data for Oral Cavity Cancer.

Sources

Pathways for Oral Cavity Cancer

Pathways related to Oral Cavity Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 61)

#	Super pathways	Score	Top Affiliating Genes
1	Innate Immune System ⁶⁷ Show member pathways Immune System ⁶⁷ Neutrophil degranulation ⁶⁷	14.05	BST2 CASP8 EGFR ERBB2 FADD MCL1
2	ERK Signaling ⁶⁵ Show member pathways ILK Signaling ⁶⁵ MAPK Signaling ⁶⁵ Molecular Mechanisms of Cancer ⁶⁵ Rho Family GTPases ⁶⁵	13.87	BAX CASP8 EGFR ERBB2 FADD GDF15
3	Akt Signaling ⁶⁵ Show member pathways p38 Signaling ⁶⁵ Tec Kinases Signaling ⁶⁵	13.4	BAX EGFR ERBB2 FADD GDF15 PTEN
4	Cytokine Signaling in Immune system ⁶⁷ Show member pathways Signaling by Interleukins ⁶⁷	13.37	BST2 EGFR ERBB2 MCL1 PIK3CA SOX2
5	PAK Pathway ⁶⁵ Show member pathways Antioxidant Action of Vitamin-C ⁶⁵ Epithelial Adherens Junctions ⁶⁵	13.31	BAX CASP8 EGFR ERBB2 GDF15 PTEN
6	Development Angiotensin activation of ERK ²³ Show member pathways Cell adhesion Integrin inside-out signaling ²³ Development ACM2 and ACM4 activation of ERK ²³ Development Angiotensin signaling via PYK2 ²³ Development EDNRB signaling ²³ Development EPO-induced MAPK pathway ²³ Development G-Proteins mediated regulation MARK-ERK signaling ²³ Signal transduction IP3 signaling ²³	12.93	CASP8 EDNRB EGFR FADD PIK3CA TNFRSF10B
7	Focal Adhesion ¹ ³⁸ Show member pathways HGF Pathway ⁶⁵ Integrin-mediated Cell Adhesion ¹	12.89	EGFR ERBB2 PIK3CA PTEN VEGFA
8	TNFR1 Pathway ⁶⁵ Show member pathways Apoptosis and survival TNFR1 signaling pathway ²³ Apoptosis through Death Receptors ⁶⁵ Apoptotic Pathways Triggered By HIV1 ⁶⁵ DR3 Signaling ⁶⁵ Fas Signaling ⁶⁵ GITR Pathway ⁶⁵ HIV-1 Nef- Negative effector of Fas and TNF-alpha ¹ Stimulation of the cell death response by PAK-2p34 ⁶⁷ TNF alpha Signaling Pathway ¹ TNF related weak inducer of apoptosis (TWEAK) Signaling Pathway ¹ TNF Signaling ⁶⁵ TRAIL Pathway ⁶⁵ TWEAK Pathway ⁶⁵	12.88	BAX CASP8 EGFR FADD PIK3CA PTEN
9	Endometrial cancer ³⁸ Show member pathways Acute myeloid leukemia ³⁸ Binding of TCF/LEF-CTNNB1 to target gene promoters ⁶⁷ Chronic myeloid leukemia ³⁸ Colorectal cancer ³⁸ Pancreatic cancer ³⁸ Prostate cancer ³⁸ Signal transduction PTEN pathway ²³ Thyroid cancer ³⁸	12.84	BAX EGFR ERBB2 PIK3CA PTEN VEGFA
10	Human cytomegalovirus infection ³⁸ Show member pathways Human immunodeficiency virus 1 infection ³⁸ Kaposi sarcoma-associated herpesvirus infection ³⁸	12.82	BAX BST2 CASP8 EGFR FADD PIK3CA
11	Apoptosis Modulation and Signaling ¹ Show member pathways Apoptosis ³⁸ Apoptosis ¹ Apoptosis and survival Apoptotic TNF-family pathways ²³ Apoptosis Signaling Pathways ⁶⁶ Death Receptor Signaling ⁶⁸	12.79	BAX CASP8 FADD MCL1 PIK3CA TNFRSF10B
12	Gastric cancer ³⁸ Show member pathways Breast cancer ³⁸ Hepatocellular carcinoma ³⁸	12.73	BAX EGFR ERBB2 GSTM1 PIK3CA PTEN
13	PI3K-Akt signaling pathway ³⁸ Show member pathways Human papillomavirus infection ³⁸	12.69	BAX CASP8 EGFR ERBB2 FADD MCL1
14	Glioma ³⁸ Show member pathways Endocrine resistance ³⁸ Melanoma ³⁸ Non-small cell lung cancer ³⁸ Signaling Pathways in Glioblastoma ¹	12.66	BAX EGFR ERBB2 PIK3CA PTEN VEGFA
15	Influenza A ³⁸ Show member pathways Measles ³⁸	12.59	CASP8 FADD PIK3CA TLR2 TNFRSF10B
16	ErbB signaling pathway ¹ ³⁸ Show member pathways EGFR Inhibitor Pathway, Pharmacodynamics ⁶² EGFR tyrosine kinase inhibitor resistance ³⁸ Renal cell carcinoma ³⁸ TCA Cycle Nutrient Utilization and Invasiveness of Ovarian Cancer ¹	12.58	EGFR ERBB2 PIK3CA VEGFA
17	TRAF Pathway ⁶⁵ Show member pathways 14-3-3 Induced Apoptosis ⁶⁵ TNF Superfamily Pathway ⁶⁵ Toll-Like Receptors Pathway ⁶⁵	12.58	CASP8 FADD PIK3CA TLR2 TNFRSF10B VEGFA
18	Development Endothelin-1/EDNRA signaling ²³ Show member pathways Cytoskeleton remodeling FAK signaling ²³ Development Endothelin-1/EDNRA transactivation of EGFR ²³ GnRH signaling pathway ³⁸ Inflammatory mediator regulation of TRP channels ³⁸	12.57	CASP8 EGFR FADD PIK3CA PTEN TNFRSF10B
19	mTOR signaling pathway (KEGG) ⁶⁶ Show member pathways mTOR signaling pathway ³⁸	12.49	EGFR ERBB2 PIK3CA PTEN
20	Prolactin Signaling Pathway ¹ ³⁸ Show member pathways Development Prolactin receptor signaling ²³ Leptin signaling pathway ¹	12.48	BAX ERBB2 PIK3CA PTEN
21	MicroRNAs in cancer ³⁸	12.46	EGFR ERBB2 MCL1 PIK3CA PTEN VEGFA
22	Apoptosis Pathway ⁷³ Show member pathways Akt Pathway ⁷³ NF-kappaB Pathway ⁷³	12.42	BAX CASP8 EGFR ERBB2 PIK3CA
23	DNA Damage Response ¹ Show member pathways miRNA Regulation of DNA Damage Response ¹ p53 signaling pathway ³⁸	12.38	BAX CASP8 PTEN TNFRSF10B
24	p53 Signaling ⁶⁵ Show member pathways p53 Pathway ⁶⁸	12.26	BAX CASP8 PTEN TNFRSF10B
25	Proteoglycans in cancer ³⁸	12.25	EGFR ERBB2 PIK3CA TLR2 VEGFA
26	Tuberculosis ³⁸	12.24	BAX CASP8 FADD TLR2
27	Necroptosis ³⁸ Show member pathways Nanoparticle triggered regulated necrosis ¹	12.23	BAX CASP8 FADD TNFRSF10B
28	Colorectal Cancer Metastasis ⁶⁵	12.19	BAX EGFR TLR2 VEGFA
29	MAPK Signaling: Mitogen Stimulation Pathway ⁶⁶ Show member pathways Akt Signaling Pathway ⁶⁶	12.19	BAX EGFR ERBB2 PIK3CA PTEN
30	Apoptosis and Autophagy ⁴	12.15	BAX CASP8 FADD GDF15 MCL1 TNFRSF10B
31	Development EGFR signaling via small GTPases ²³ Show member pathways Development EGFR signaling via PIP3 ²³ Development PDGF signaling via MAPK cascades ²³ PDGF Pathway ¹	12.13	EGFR ERBB2 PIK3CA PTEN
32	Transcription Androgen Receptor nuclear signaling ²³ Show member pathways Translation Non-genomic (rapid) action of Androgen Receptor ²³	12.1	EGFR ERBB2 PIK3CA PTEN
33	Immune response IFN gamma signaling pathway ²³ Show member pathways IFN-gamma pathway ¹	12.09	BAX EGFR GDF15 PIK3CA TNFRSF10B
34	AKT Signaling Pathway ⁶⁸	12.09	BAX EGFR ERBB2 PIK3CA PTEN
35	FoxO signaling pathway ³⁸ Show member pathways PLK2 and PLK4 events ¹ Polo-like kinase signaling events in the cell cycle ¹	12.07	EGFR PIK3CA PTEN SOD2
36	Pathways in cancer ³⁸	12.05	BAX CASP8 EDNRB EGFR ERBB2 FADD
37	Integrated Breast Cancer Pathway ¹	11.99	BAX CASP8 EGFR FADD PTEN VEGFA
38	MAPK Pathway ⁷³ Show member pathways Toll-like Receptor Pathway ⁷³	11.97	CASP8 EGFR ERBB2 PIK3CA TLR2
39	DNA Damage Response (only ATM dependent) ¹	11.92	BAX ERBB2 PIK3CA PTEN SOD2
40	AGE-RAGE signaling pathway in diabetic complications ³⁸	11.9	BAX PIK3CA VEGFA
41	HIF-1 signaling pathway ³⁸	11.88	EGFR ERBB2 PIK3CA VEGFA
42	Small cell lung cancer ³⁸	11.86	BAX PIK3CA PTEN
43	Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors ⁶⁷ Show member pathways Activation of the TFAP2 (AP-2) family of transcription factors ⁶⁷ Negative regulation of activity of TFAP2 (AP-2) family transcription factors ⁶⁷ TFAP2 (AP-2) family regulates transcription of cell cycle factors ⁶⁷ TFAP2 (AP-2) family regulates transcription of growth factors and their receptors ⁶⁷ TFAP2 (AP-2) family regulates transcription of other transcription factors ⁶⁷ TFAP2A acts as a transcriptional repressor during retinoic acid induced cell differentiation ⁶⁷	11.86	EGFR ERBB2 VEGFA
44	Direct p53 effectors ¹	11.85	BAX EGFR GDF15 MCL1 PTEN TNFRSF10B
45	VEGF Pathway (Tocris) ⁷³ Show member pathways Sorafenib Pharmacodynamics ⁶²	11.81	BAX CASP8 PIK3CA
46	Nanomaterial induced apoptosis ¹ Show member pathways Activation and oligomerization of BAK protein ⁶⁷ Apoptosis - multiple species ³⁸ Apoptosis Modulation by HSP70 ¹ Apoptotic factor-mediated response ⁶⁷ Release of apoptotic factors from the mitochondria ⁶⁷	11.78	BAX CASP8 FADD MCL1
47	Bladder cancer ³⁸ ¹	11.74	EGFR ERBB2 VEGFA
48	Pathways Affected in Adenoid Cystic Carcinoma ¹	11.69	ERBB2 PIK3CA PTEN
49	Central carbon metabolism in cancer ³⁸	11.64	EGFR ERBB2 PIK3CA PTEN
50	Photodynamic therapy-induced AP-1 survival signaling. ¹	11.57	BAX EGFR MCL1

Sources

GO Terms for Oral Cavity Cancer

Cellular components related to Oral Cavity Cancer according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	cytoplasm	GO:0005737	9.86	BAX BST2 CASP8 CYP1A1 EGFR ERBB2
2	cell body	GO:0044297	9.58	CASP8 FADD TLR2
3	death-inducing signaling complex	GO:0031264	9.37	CASP8 FADD
4	Bcl-2 family protein complex	GO:0097136	9.32	BAX MCL1
5	CD95 death-inducing signaling complex	GO:0031265	9.26	CASP8 FADD
6	ripoptosome	GO:0097342	9.16	CASP8 FADD
7	membrane raft	GO:0045121	9.1	BST2 CASP8 EDNRB EGFR FADD TLR2

Biological processes related to Oral Cavity Cancer according to GeneCards Suite gene sharing:

(show all 40)

#	Name	GO ID	Score	Top Affiliating Genes
1	cytokine-mediated signaling pathway	GO:0019221	9.98	MCL1 PIK3CA SOX2 VEGFA
2	apoptotic process	GO:0006915	9.98	BAX CASP8 FADD MCL1 PTEN TLR2
3	negative regulation of apoptotic process	GO:0043066	9.95	EDNRB EGFR MCL1 PTEN VEGFA
4	positive regulation of protein phosphorylation	GO:0001934	9.91	EDNRB EGFR ERBB2 VEGFA
5	aging	GO:0007568	9.9	CYP1A1 EDNRB PTEN SOD2
6	positive regulation of I-kappaB kinase/NF-kappaB signaling	GO:0043123	9.89	BST2 CASP8 FADD TNFRSF10B
7	positive regulation of protein kinase B signaling	GO:0051897	9.88	EGFR ERBB2 GDF15 PIK3CA
8	response to lipopolysaccharide	GO:0032496	9.88	CASP8 CYP1A1 EDNRB TLR2
9	response to toxic substance	GO:0009636	9.85	BAX CYP1A1 TLR2
10	cell proliferation	GO:0008283	9.85	BAX BST2 CYP1A1 EGFR ERBB2 PTEN
11	positive regulation of peptidyl-serine phosphorylation	GO:0033138	9.83	EGFR PIK3CA VEGFA
12	liver development	GO:0001889	9.83	CYP1A1 EGFR PIK3CA
13	response to organic cyclic compound	GO:0014070	9.83	CYP1A1 EDNRB EGFR PTEN
14	response to wounding	GO:0009611	9.82	BAX CYP1A1 SOX2
15	apoptotic signaling pathway	GO:0097190	9.81	BAX CASP8 FADD
16	positive regulation of epithelial cell proliferation	GO:0050679	9.8	EGFR ERBB2 VEGFA
17	positive regulation of MAP kinase activity	GO:0043406	9.8	EGFR ERBB2 VEGFA
18	activation of cysteine-type endopeptidase activity involved in apoptotic process	GO:0006919	9.76	BAX CASP8 FADD TNFRSF10B
19	extrinsic apoptotic signaling pathway	GO:0097191	9.74	BAX CASP8 FADD
20	cell surface receptor signaling pathway	GO:0007166	9.73	CASP8 EDNRB EGFR ERBB2 FADD TNFRSF10B
21	positive regulation of MAPK cascade	GO:0043410	9.71	ERBB2 GDF15 SOX2
22	cellular response to mechanical stimulus	GO:0071260	9.71	CASP8 EGFR FADD TNFRSF10B
23	negative regulation of extrinsic apoptotic signaling pathway via death domain receptors	GO:1902042	9.69	CASP8 FADD TNFRSF10B
24	negative regulation of phagocytosis	GO:0050765	9.68	PTEN TLR2
25	activation of cysteine-type endopeptidase activity	GO:0097202	9.67	CASP8 FADD
26	positive regulation of macrophage differentiation	GO:0045651	9.67	CASP8 FADD
27	regulation of cysteine-type endopeptidase activity involved in apoptotic process	GO:0043281	9.67	BAX SOX2
28	extrinsic apoptotic signaling pathway in absence of ligand	GO:0097192	9.67	BAX FADD MCL1
29	response to arsenic-containing substance	GO:0046685	9.66	CYP1A1 PTEN
30	toll-like receptor 3 signaling pathway	GO:0034138	9.65	CASP8 FADD
31	ERBB2 signaling pathway	GO:0038128	9.65	EGFR ERBB2 PIK3CA
32	death-inducing signaling complex assembly	GO:0071550	9.64	CASP8 FADD
33	regulation of apoptotic process	GO:0042981	9.63	BAX CASP8 FADD GDF15 MCL1 TNFRSF10B
34	regulation of necroptotic process	GO:0060544	9.62	CASP8 FADD
35	negative regulation of ERBB signaling pathway	GO:1901185	9.61	EGFR ERBB2
36	activation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway	GO:0097296	9.56	BAX CASP8
37	regulation of extrinsic apoptotic signaling pathway via death domain receptors	GO:1902041	9.5	CASP8 FADD TNFRSF10B
38	extrinsic apoptotic signaling pathway via death domain receptors	GO:0008625	9.26	BAX CASP8 FADD TNFRSF10B
39	TRAIL-activated apoptotic signaling pathway	GO:0036462	8.8	CASP8 FADD TNFRSF10B
40	nervous system development	GO:0007399	10.05	BAX EDNRB ERBB2 PTEN VEGFA

Molecular functions related to Oral Cavity Cancer according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	protein homodimerization activity	GO:0042803	9.88	BAX BST2 GDF15 GSTM1 MCL1 VEGFA
2	phosphatidylinositol-4,5-bisphosphate 3-kinase activity	GO:0046934	9.54	EGFR ERBB2 PIK3CA
3	death receptor binding	GO:0005123	9.46	CASP8 FADD
4	platelet-derived growth factor receptor binding	GO:0005161	9.43	PTEN VEGFA
5	protein heterodimerization activity	GO:0046982	9.43	BAX EGFR ERBB2 MCL1 TLR2 VEGFA
6	identical protein binding	GO:0042802	9.32	BAX BST2 CASP8 EGFR ERBB2 FADD
7	BH3 domain binding	GO:0051434	9.26	BAX MCL1
8	death effector domain binding	GO:0035877	9.16	CASP8 FADD
9	protein binding	GO:0005515	10.25	BAX BST2 CASP8 CYP1A1 EDNRB EGFR

Sources

Sources for Oral Cavity Cancer

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FDA Approved Drugs

²⁰ FMA

²¹ GeneAnalytics

²² GeneCards

²³ GeneGo (Thomson Reuters)

²⁴ GeneHancer via GeneCards

²⁵ GeneReviews

²⁶ Genetics Home Reference

²⁷ GenomeRNAi

²⁸ GEO DataSets

²⁹ GO

³⁰ GTR

³¹ HGMD

³² HMDB

³³ HPO

³⁴ ICD10

³⁵ ICD10 via Orphanet

³⁶ ICD9CM

³⁷ IUPHAR

³⁸ KEGG

³⁹ LifeMap

⁴⁰ LncRNADisease

⁴¹ LOVD

⁴² MalaCards

⁴³ MedGen

⁴⁴ MedlinePlus

⁴⁵ MeSH

⁴⁶ MESH via Orphanet

⁴⁷ MGI

⁴⁸ miR2Disease

⁴⁹ NCBI Bookshelf

⁵⁰ NCI

⁵¹ NCIt

⁵² NDF-RT

⁵³ NIH Clinical Center

⁵⁴ NIH Rare Diseases

⁵⁵ NINDS

⁵⁶ Novoseek

⁵⁷ Novus Biologicals

⁵⁸ OMIM

⁵⁹ OMIM via Orphanet

⁶⁰ Orphanet

⁶¹ PathCards

⁶² PharmGKB

⁶³ PubMed

⁶⁴ PubMed Health

⁶⁵ QIAGEN

⁶⁶ R&D Systems

⁶⁷ Reactome

⁶⁸ Sino Biological

⁶⁹ SNOMED-CT

⁷⁰ SNOMED-CT via HPO

⁷¹ SNOMED-CT via Orphanet

⁷² TGDB

⁷³ Tocris

⁷⁴ UMLS

⁷⁵ UMLS via Orphanet

⁷⁶ UniProtKB/Swiss-Prot

⁷⁷ Wikipedia